Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194019 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL14929306 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL12374613 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11982565 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL16884139 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL12302343 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL1739854 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11965635 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL24672314 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL8815319 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-2231689-B1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2016-07-20 | — | — | EP | disclosed |
| US-8093226-B2 | Cytostatic 7-deazapurine nucleosides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2012-01-10 | — | — | US | disclosed |
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CA2 4675/4885CA1 4802/4885CA9 4604/4885 |
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | TYMP, TYMS, DPYD | CA2 3997/4885CA1 2760/4885CA9 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.